243 related articles for article (PubMed ID: 27835583)
1. Non-invasive diagnosis of papillary thyroid microcarcinoma: a NMR-based metabolomics approach.
Lu J; Hu S; Miccoli P; Zeng Q; Liu S; Ran L; Hu C
Oncotarget; 2016 Dec; 7(49):81768-81777. PubMed ID: 27835583
[TBL] [Abstract][Full Text] [Related]
2. Combination of serum microRNAs and ultrasound profile as predictive biomarkers of diagnosis and prognosis for papillary thyroid microcarcinoma.
Zhang Y; Pan J; Xu D; Yang Z; Sun J; Sun L; Wu Y; Qiao H
Oncol Rep; 2018 Dec; 40(6):3611-3624. PubMed ID: 30542708
[TBL] [Abstract][Full Text] [Related]
3. Deciphering novel biomarkers of lymph node metastasis of thyroid papillary microcarcinoma using proteomic analysis of ultrasound-guided fine-needle aspiration biopsy samples.
Lin P; Yao Z; Sun Y; Li W; Liu Y; Liang K; Liu Y; Qin J; Hou X; Chen L
J Proteomics; 2019 Jul; 204():103414. PubMed ID: 31195151
[TBL] [Abstract][Full Text] [Related]
4. Metabolic changes associated with papillary thyroid carcinoma: A nuclear magnetic resonance-based metabolomics study.
Li Y; Chen M; Liu C; Xia Y; Xu B; Hu Y; Chen T; Shen M; Tang W
Int J Mol Med; 2018 May; 41(5):3006-3014. PubMed ID: 29484373
[TBL] [Abstract][Full Text] [Related]
5. Plasma metabolites analysis of patients with papillary thyroid cancer: A preliminary untargeted
Razavi SA; Mahmanzar M; Nobakht M Gh BF; Zamani Z; Nasiri S; Hedayati M
J Pharm Biomed Anal; 2024 Apr; 241():115946. PubMed ID: 38241910
[TBL] [Abstract][Full Text] [Related]
6. Metabolomics of papillary thyroid carcinoma tissues: potential biomarkers for diagnosis and promising targets for therapy.
Shang X; Zhong X; Tian X
Tumour Biol; 2016 Aug; 37(8):11163-75. PubMed ID: 26935059
[TBL] [Abstract][Full Text] [Related]
7. Preoperative ultrasonography and serum thyroid-stimulating hormone on predicting central lymph node metastasis in thyroid nodules as or suspicious for papillary thyroid microcarcinoma.
Gao Y; Qu N; Zhang L; Chen JY; Ji QH
Tumour Biol; 2016 Jun; 37(6):7453-9. PubMed ID: 26678888
[TBL] [Abstract][Full Text] [Related]
8. Serum-plasma matched metabolomics for comprehensive characterization of benign thyroid nodule and papillary thyroid carcinoma.
Huang FQ; Li J; Jiang L; Wang FX; Alolga RN; Wang MJ; Min WJ; Ma G; Zhao YJ; Wang SL; Yu Y; Chen X; Zhu D; Zhu J; Wang G; Xia T; Sang JF; Lai MD; Li P; Zhu W; Qi LW
Int J Cancer; 2019 Feb; 144(4):868-876. PubMed ID: 30318614
[TBL] [Abstract][Full Text] [Related]
9. Papillary thyroid microcarcinoma: how to diagnose and manage this epidemic?
Soares P; Celestino R; Gaspar da Rocha A; Sobrinho-Simões M
Int J Surg Pathol; 2014 Apr; 22(2):113-9. PubMed ID: 24401191
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological, immunohistochemical factors and recurrence associated with extrathyroidal extension in papillary thyroid microcarcinoma.
Kim WY; Kim HY; Son GS; Bae JW; Lee JB
J Cancer Res Ther; 2014; 10(1):50-5. PubMed ID: 24762486
[TBL] [Abstract][Full Text] [Related]
11. High Serum TSH Level Is Associated With Progression of Papillary Thyroid Microcarcinoma During Active Surveillance.
Kim HI; Jang HW; Ahn HS; Ahn S; Park SY; Oh YL; Hahn SY; Shin JH; Kim JH; Kim JS; Chung JH; Kim TH; Kim SW
J Clin Endocrinol Metab; 2018 Feb; 103(2):446-451. PubMed ID: 29211863
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical analysis based Ep-ICD subcellular localization index (ESLI) is a novel marker for metastatic papillary thyroid microcarcinoma.
Kunavisarut T; Kak I; Macmillan C; Ralhan R; Walfish PG
BMC Cancer; 2012 Nov; 12():523. PubMed ID: 23153310
[TBL] [Abstract][Full Text] [Related]
13. Can galectin-3 be a useful marker for conventional papillary thyroid microcarcinoma?
Gweon HM; Kim JA; Youk JH; Hong SW; Lim BJ; Yoon SO; Park YM; Son EJ
Diagn Cytopathol; 2016 Feb; 44(2):103-7. PubMed ID: 26681546
[TBL] [Abstract][Full Text] [Related]
14. Papillary thyroid microcarcinoma might progress during pregnancy.
Shindo H; Amino N; Ito Y; Kihara M; Kobayashi K; Miya A; Hirokawa M; Miyauchi A
Thyroid; 2014 May; 24(5):840-4. PubMed ID: 24397849
[TBL] [Abstract][Full Text] [Related]
15. Distinct Metabolomic Profiles of Papillary Thyroid Carcinoma and Benign Thyroid Adenoma.
Xu Y; Zheng X; Qiu Y; Jia W; Wang J; Yin S
J Proteome Res; 2015 Aug; 14(8):3315-21. PubMed ID: 26130307
[TBL] [Abstract][Full Text] [Related]
16. Risk factors contributing to the difference in prognosis for papillary versus micropapillary thyroid carcinoma.
Karatzas T; Vasileiadis I; Kapetanakis S; Karakostas E; Chrousos G; Kouraklis G
Am J Surg; 2013 Oct; 206(4):586-93. PubMed ID: 23790258
[TBL] [Abstract][Full Text] [Related]
17. Metabolomics as a potential method for predicting thyroid malignancy in children and adolescents.
Zhou Q; Zhang LY; Xie C; Zhang ML; Wang YJ; Liu GH
Pediatr Surg Int; 2020 Feb; 36(2):145-153. PubMed ID: 31576470
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological Features and Prognosis of Papillary Thyroid Microcarcinoma for Surgery and Relationships with the BRAFV600E Mutational Status and Expression of Angiogenic Factors.
Shi C; Guo Y; Lv Y; Nanding A; Shi T; Qin H; He J
PLoS One; 2016; 11(12):e0167414. PubMed ID: 27936049
[TBL] [Abstract][Full Text] [Related]
19. Preoperative prediction of papillary thyroid microcarcinoma via multiparameter ultrasound.
Ma HJ; Yang JC; Leng ZP; Chang Y; Kang H; Teng LH
Acta Radiol; 2017 Nov; 58(11):1303-1311. PubMed ID: 28194993
[TBL] [Abstract][Full Text] [Related]
20. Real-Time PCR Cycle Threshold Values for the BRAFV600E Mutation in Papillary Thyroid Microcarcinoma May Be Associated With Central Lymph Node Metastasis: A Retrospective Study.
Park VY; Kim EK; Lee HS; Moon HJ; Yoon JH; Kwak JY
Medicine (Baltimore); 2015 Jul; 94(28):e1149. PubMed ID: 26181555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
